Oncology

But there is no benefit for patients receiving chemotherapy.

Kite plans to submit a supplemental BLA based on these findings.

The anticancer therapy is now available in 21-count bottles to help accommodate dispensing.

A new indication, a nonprescription switch, a recall, and new guidances round out this week’s FDA news.

The therapy is a modified poliovirus vaccine that not only kills cancer cells but also can trigger long-term immune memory.

Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.

Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.

A large proportion of patients with muscle-invasive bladder cancer responded to transurethral resection of bladder tumor and a drug cocktail that included gemcitabine, cisplatin and Opdivo (nivolumab).

The Association of Community Cancer Centers launched the ACCC Community Oncology Research Institute, which builds on the organization's mission to close the gap in cancer research through optimal community oncology partnerships.

About 2% to 3% of patients with nonsmall cell lung cancer have EGFR exon 20 insertion mutations targeted by newly approved Rybrevant.

A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.

Opdivo is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

The FDA approved proton beam radiation in 1988. But whether it is an improvement over conventional photon radiation as a treatment for many cancers remains an open question.

Automated texts may also lessen the workload on nurses.

COTA’s real-world data and Kite's drug development pipeline will complement single-arm clinical trials to accelerate cancer research benefiting patients.

Screening and some care have been canceled or deferred. Will more illness and deaths result?

The decision by Roche comes shortly after AstraZeneca withdrew the bladder cancer indication for durvalumab (Imfinzi).

NCI Director Norman Sharpless discussed deferred care, missed screening and his future at the institute in an interview with Managed Healthcare Executive.

Adjustments to payment models are beginning to take social determinants into account.

One of the new treatments available is a CAR-T cell therapy to treat relapsed or refractory large B-cell lymphoma.

Payer strains now top the list of stressors facing oncologists, with prior authorization as the most-cited source of that payer stress.

The pandemic has led to the adoption of telehealth and greater access to care through apps.

The organizations give recommendations on how to get patients to receive the care they need.

FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).

Deposing the ‘Emperor of All Maladies’ will take a diverse toolkit, not a single moonshot.

New treatment for metastatic HER2-positive breast cancer is called Margenza.

More oncologists are experiencing burnout due to the loss of face-to-face interactions with patients, according to a report from Cardinal Health Specialty Solutions.

Drug and diagnostic approvals and biosimilars news were popular with readers.